3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Small Cell Lung Carcinoma
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Smoking
1
Multiple Myeloma
1
Leukemia, Plasma Cell
1
Hematologic Neoplasms
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
Dexamethasone
6
fludarabine
5
Whole-Body Irradiation
5
Mycophenolic Acid
5
Melphalan
5
Lenalidomide
5
Cyclophosphamide
5
fludarabine phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Tacrolimus
3
Calcium Dobesilate
3
Bortezomib
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
daratumumab
2
auricularum
2
Stem Cell Transplantation
2
Sirolimus
2
Antilymphocyte Serum
2
Allopurinol
2
pomalidomide
1
plerixafor
1
pegylated granulocyte colony-stimulating factor
1
liposomal doxorubicin
1
ixazomib
1
isatuximab
1
ferric pyrophosphate
1
elotuzumab
1
carmustine, poliferprosan 20 drug combination
1
carfilzomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia, Plasma Cell
×
Budesonide
×
Clear all
NCT05405387
2026-06-05
IMPACT
University of Utah
Phase 2
Recruiting
120 enrolled